CD47 and lymphoma: In order to further improve HuNb1-IgG4 safety and efficacy, we also established anti-CD47/CD20 bispecific antibody (BsAb) consisted of HuNb1 and Rituximab, showing more preference binding to tumor cells and more potent anti-lymphoma activity compared to HuNb1-IgG4.